Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ)
CNY 32.71
(-0.58%)
CNY 32.71
(-0.58%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.53 Million CNY | -35.97% |
| 2022 | 19.58 Million CNY | 114.9% |
| 2021 | 9.11 Million CNY | -89.87% |
| 2020 | 90 Million CNY | -43.37% |
| 2019 | 158.92 Million CNY | -34.34% |
| 2018 | 242.04 Million CNY | 706.8% |
| 2017 | 30 Million CNY | -33.33% |
| 2016 | 45 Million CNY | -25.0% |
| 2015 | 60 Million CNY | 0.0% |
| 2014 | - CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| 2008 | - CNY | -100.0% |
| 2007 | 5 Million CNY | 0.0% |
| 2006 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 8.06 Million CNY | -100.0% |
| 2024 Q2 | 4.95 Million CNY | 0.0% |
| 2024 Q3 | 5.13 Million CNY | 0.0% |
| 2023 Q4 | 12.53 Million CNY | -41.39% |
| 2023 Q3 | 21.39 Million CNY | 29.95% |
| 2023 Q2 | 16.46 Million CNY | -15.77% |
| 2023 FY | 12.53 Million CNY | -35.97% |
| 2023 Q1 | 19.54 Million CNY | -0.19% |
| 2022 Q1 | 7.57 Million CNY | -16.83% |
| 2022 FY | 19.58 Million CNY | 114.9% |
| 2022 Q4 | 19.58 Million CNY | -32.48% |
| 2022 Q3 | 29 Million CNY | 338.85% |
| 2022 Q2 | 6.6 Million CNY | -12.81% |
| 2021 Q1 | 100.69 Million CNY | 11.89% |
| 2021 FY | 9.11 Million CNY | -89.87% |
| 2021 Q4 | 9.11 Million CNY | -36.77% |
| 2021 Q3 | 14.41 Million CNY | -85.2% |
| 2021 Q2 | 97.36 Million CNY | -3.31% |
| 2020 Q4 | 90 Million CNY | 0.0% |
| 2020 Q1 | 287.3 Million CNY | 80.78% |
| 2020 FY | 90 Million CNY | -43.37% |
| 2020 Q3 | 90 Million CNY | -72.3% |
| 2020 Q2 | 324.87 Million CNY | 13.08% |
| 2019 Q2 | 214.33 Million CNY | -11.45% |
| 2019 Q1 | 242.04 Million CNY | 0.0% |
| 2019 FY | 158.92 Million CNY | -34.34% |
| 2019 Q4 | 158.92 Million CNY | -29.08% |
| 2019 Q3 | 224.08 Million CNY | 4.55% |
| 2018 Q4 | 242.04 Million CNY | 56.56% |
| 2018 Q3 | 154.59 Million CNY | 518.4% |
| 2018 FY | 242.04 Million CNY | 706.8% |
| 2018 Q2 | 25 Million CNY | -16.67% |
| 2018 Q1 | 30 Million CNY | 0.0% |
| 2017 Q3 | 40 Million CNY | 0.0% |
| 2017 Q2 | 40 Million CNY | -11.11% |
| 2017 FY | 30 Million CNY | -33.33% |
| 2017 Q4 | 30 Million CNY | -25.0% |
| 2017 Q1 | 45 Million CNY | 0.0% |
| 2016 FY | 45 Million CNY | -25.0% |
| 2016 Q4 | 45 Million CNY | -25.0% |
| 2016 Q1 | 60 Million CNY | 0.0% |
| 2016 Q3 | 60 Million CNY | 0.0% |
| 2016 Q2 | 60 Million CNY | 0.0% |
| 2015 Q4 | 60 Million CNY | 0.0% |
| 2015 FY | 60 Million CNY | 0.0% |
| 2015 Q3 | 60 Million CNY | 0.0% |
| 2015 Q1 | - CNY | 0.0% |
| 2015 Q2 | - CNY | 0.0% |
| 2014 Q4 | - CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 Q3 | - CNY | 0.0% |
| 2014 FY | - CNY | 0.0% |
| 2014 Q2 | - CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q1 | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2011 Q1 | - CNY | 0.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 Q2 | - CNY | 0.0% |
| 2010 Q1 | - CNY | 0.0% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2010 Q3 | - CNY | 0.0% |
| 2009 Q3 | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| 2009 Q2 | - CNY | 0.0% |
| 2009 Q4 | - CNY | 0.0% |
| 2008 Q4 | - CNY | 0.0% |
| 2008 FY | - CNY | -100.0% |
| 2007 FY | 5 Million CNY | 0.0% |
| 2006 FY | - CNY | 0.0% |